Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine October 2014, 55 (10) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

Hyperpolarized 13C MRS in prostate cancer: Wilson and Kurhanewicz identify metabolic shifts seen in cancer that may be exploited for diagnosis, with a special focus on agents and platforms developed for hyperpolarized 13C MR spectroscopy.

Page 1567

Clinical readiness of quantitative SPECT: Liu and Sinusas look at the promise and challenges associated with practical assessment of absolute myocardial perfusion with dynamic SPECT imaging.

Page 1573

Diagnostic imaging in NETs: Mansi and Cuccurullo offer perspective on PET/CT with DOTA peptides in diagnosis and staging of patients with neuroendocrine tumors and preview a related article in this issue of JNM.

Page 1576

PET/CT in young breast cancer patients: Riedl and colleagues retrospectively evaluate the utility of 18F-FDG PET/CT staging in a group of asymptomatic breast cancer patients younger than 40 years of age.

Page 1578

PET and NSCLC survival: Huang and colleagues explore the value of standardized uptake values and metabolic tumor volumes on 18F-FDG PET/CT in predicting survival in locally advanced non–small cell lung cancer during early stages of concurrent chemoradiotherapy.

Page 1584

Improving DLBCL prognosis: Cerci and colleagues report on data from a multinational study of PET and risk assessment in diffuse large B-cell lymphoma, looking specifically at marrow involvement identified by staging PET and routine bone marrow biopsy for predicting outcomes.

Page 1591

NET imaging assessment: Etchebehere and colleagues compare the relative capabilities of 99mTc-HYNIC-octreotide SPECT/CT, 68Ga-DOTATATE PET/CT, and whole-body diffusion-weighted MR imaging in patients with neuroendocrine tumors.

Page 1598

Tryptophan uptake in nontumoral brain: Kamson and colleagues investigate clinical correlates of tryptophan metabolic abnormalities in the nontumoral hemisphere of glioma patients using α-11C-methyl-l-tryptophan PET.

Page 1605

Amino acid–based PET in glioblastoma: Lapa and colleagues compare information provided by 18F-FET and 18F-DOPA in PET/CT imaging of patients with high-grade gliomas.

Page 1611

18F-FP-CIT PET/MR and AC: Choi and colleagues evaluate quantification of 18F-FP-CIT binding in brain PET/MR, focusing on the effects of ultrashort echo time–based attenuation correction including bone segmentation.

Page 1617

Categorizing 18F-flutemetamol PET: Thurfjell and colleagues assess a fully automated quantification method for classifying 18F-flutemetamol PET studies as negative or positive for brain amyloid.

Page 1623

Myocardial uptake suppression on PET: Demeure and colleagues investigate the efficacies of different interventions for suppressing myocardial 18F-FDG uptake in PET/CT detection of arterial atherosclerotic plaque inflammation.

Page 1629

212Pb radioimmunotherapy: Meredith and colleagues report on the safety, distribution, pharmacokinetics, immunogenicity, and tumor response of intraperitoneal 212Pb-TCMC-trastuzumab in patients with human epidermal growth factor receptor type 2–expressing malignancy.

Page 1636

Fat-MR–constrained PET reconstruction: Prevrhal and colleagues describe potential improvements in 18F-FDG PET image quality using a technique to constrain PET image reconstruction to low-fat regions, with the rationale that fatty tissue metabolism is low in glucose consumption.

Page 1643

Targeting neuropeptide receptors in tumors: Morgat and colleagues provide an educational overview of the biology and roles of bombesin, neurotensin, and neuropeptide-Y receptor systems that offer high potential in the field of nuclear oncology.

Page 1650

47Sc radionuclide therapy: Müller and colleagues investigate the suitability of 47Sc for therapy in a preclinical setting using a novel DOTA-folate conjugate with an albumin-binding entity, with promise for combined 44Sc/47Sc PET imaging and radionuclide therapy.

Page 1658

SPECT and PET in irradiated HNSCC: van Dijk and colleagues visualize changes in systemically accessible epidermal growth factor receptor with 111In-cetuximab-F(ab′)2 SPECT before and after radiotherapy for head and neck squamous cell carcinoma, with simultaneous 18F-FDG PET uptake evaluation.

Page 1665

PET estimation of ALA-induced PpIX: Suzuki and colleagues characterize the properties of 11C-labeled 5-aminolevulinic acid analog as a PET tracer to estimate protoporphyrin IX accumulation in tumors.

Page 1671

99mTc-cAbVCAM1-5 imaging: Broisat and colleagues assess the imaging sensitivity of this single-domain antibody fragment directed against mouse or human vascular cell adhesion molecule 1, with potential for detection of inflamed atherosclerotic lesions.

Page 1678

Dynamic SPECT absolute MBF: Wells and colleagues evaluate the measurement of myocardial blood flow using a multipinhole dedicated cardiac SPECT camera in a pig model of rest and transient occlusion at stress with 3 common tracers: 201Tl, 99mTc-tetrofosmin, and 99mTc-sestamibi.

Page 1685

hCTR1 as a novel imaging reporter gene: Kim and colleagues evaluate the potential for use of the human copper transporter 1 gene as a new reporter gene for tracking targeted delivery in vivo with PET using 64CuCl2.

Page 1692

oxLDL and macrophage 18F-FDG uptake: Lee and colleagues explore the effect of oxidized low-density lipoprotein on macrophage 18F-FDG uptake and investigate underlying molecular mechanisms, including the roles of hypoxia-inducible factor-1α and reactive oxygen species.

Page 1699

PET/NIR fluorescent tumor targeting: Pérez-Medina and colleagues describe the development of an 89Zr-based labeling strategy for liposomal nanoparticles that accumulate in tumors, with potential for integration into simultaneous PET and near-infrared imaging agents.

Page 1706

Adenosine 2A PET in rhesus monkeys: Barret and colleagues detail the development of a new 18F-labeled adenosine 2A PET radiotracer and explore relationships between plasma levels and A2A occupancy by preladenant and tozadenant in nonhuman primates.

Page 1712

Improved GRP receptor antagonists: Gourni and colleagues determine whether and how N-terminal modulations improve the affinity and pharmacokinetics of radiolabeled gastrin-releasing peptide receptor antagonists.

Page 1719

Imaging reactivation tuberculosis: Murawski and colleagues present a novel mouse model simulating the evolution of tuberculosis infection and reactivation disease, with implications for the use of serial 18F-FDG imaging in the study of pathogenesis and evaluation of novel therapeutics.

Page 1726

σ-receptor imaging in porcine brain: Brust and colleagues use the σ-receptor–specific agent 18F-fluspidine in swine to investigate the in vivo kinetics of the (R)-(+)- and (S)-(–)-enantiomers to identify their potential for imaging in humans.

Page 1730

PET in muscle denervation: Lee and colleagues explore the extent of glucose hypermetabolism in denervated muscle and investigate the feasibility of 18F-FDG PET imaging for detection of muscle denervation in a rat model.

Page 1737

  • © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 55 (10)
Journal of Nuclear Medicine
Vol. 55, Issue 10
October 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Oct 2014, 55 (10) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Oct 2014, 55 (10) 8A;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Dynamic SPECT Measurement of Absolute Myocardial Blood Flow in a Porcine Model
  • Promising Prospects for 44Sc-/47Sc-Based Theragnostics: Application of 47Sc for Radionuclide Tumor Therapy in Mice
  • Imaging the Evolution of Reactivation Pulmonary Tuberculosis in Mice Using 18F-FDG PET
  • Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab′)2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model
  • Clinical Significance of Tryptophan Metabolism in the Nontumoral Hemisphere in Patients with Malignant Glioma
  • Fat-Constrained 18F-FDG PET Reconstruction in Hybrid PET/MR Imaging
  • Diagnostic Imaging in Neuroendocrine Tumors
  • N-Terminal Modifications Improve the Receptor Affinity and Pharmacokinetics of Radiolabeled Peptidic Gastrin-Releasing Peptide Receptor Antagonists: Examples of 68Ga- and 64Cu-Labeled Peptides for PET Imaging
  • Oxidized Low-Density Lipoprotein Stimulates Macrophage 18F-FDG Uptake via Hypoxia-Inducible Factor-1α Activation Through Nox2-Dependent Reactive Oxygen Species Generation
  • 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial
  • A Modular Labeling Strategy for In Vivo PET and Near-Infrared Fluorescence Imaging of Nanoparticle Tumor Targeting
  • 99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice
  • Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads
  • Feasibility of 18F-FDG PET as a Noninvasive Diagnostic Tool of Muscle Denervation: A Preliminary Study
  • Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab
  • Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors
  • Value of Metabolic Tumor Volume on Repeated 18F-FDG PET/CT for Early Prediction of Survival in Locally Advanced Non–Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
  • Comparison of the Amino Acid Tracers 18F-FET and 18F-DOPA in High-Grade Glioma Patients
  • Is Assessment of Absolute Myocardial Perfusion with SPECT Ready for Prime Time?
  • Segmentation-Based MR Attenuation Correction Including Bones Also Affects Quantitation in Brain Studies: An Initial Result of 18F-FP-CIT PET/MR for Patients with Parkinsonism
  • Adenosine 2A Receptor Occupancy by Tozadenant and Preladenant in Rhesus Monkeys
  • Detection of Increased 64Cu Uptake by Human Copper Transporter 1 Gene Overexpression Using PET with 64CuCl2 in Human Breast Cancer Xenograft Model
  • Preclinical Characterization of 5-Amino-4-Oxo-[6-11C]Hexanoic Acid as an Imaging Probe to Estimate Protoporphyrin IX Accumulation Induced by Exogenous Aminolevulinic Acid
  • Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years
  • A Randomized Trial on the Optimization of 18F-FDG Myocardial Uptake Suppression: Implications for Vulnerable Coronary Plaque Imaging
  • Distinctive In Vivo Kinetics of the New σ1 Receptor Ligands (R)-(+)- and (S)-(–)-18F-Fluspidine in Porcine Brain
  • Hyperpolarized 13C MR for Molecular Imaging of Prostate Cancer
  • Combined PET and Biopsy Evidence of Marrow Involvement Improves Prognostic Prediction in Diffuse Large B-Cell Lymphoma
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire